When is it time to do more?

When is waiting no longer helping?

Don't wait while the joint gets weaker. Book an exam if soreness keeps returning or the joint feels less steady. Do the same if you're dropping normal tasks. Your doctor can compare the exam, an X-ray, and the care you've tried.

Pick a date to check your progress. By then, can you walk farther, use stairs more easily, or sleep better? If not, your home care needs another look. Don't wait for that date if fever, heat, sudden weakness, or lost movement appears.

A check date tells you whether home care is truly helping.

When should surgery enter the talk?

Discuss surgery when the joint is badly worn and your daily movement keeps shrinking. Replacement means an operation and a real recovery. It isn't the only answer for everyone. Still, a vague promise shouldn't keep you from hearing the facts.

Ask what waiting may do to your strength and balance. Ask how much strength you'll need for recovery. Then weigh any non-surgical shot against its cost, effort, and uncertain result.

Waiting too long can leave the joint stiffer and the muscles weaker.

Where does regenerative therapy fit?

Regenerative therapy means a non-surgical shot made with blood taken from you or with bone marrow. The result isn't certain. Before you book, ask how long the first visit takes, how many return trips are likely, and whether exercise or driving must change afterward so you can plan ahead. This guide can't give those details because they depend on the procedure and exam.

The letters PRP mean platelet-rich plasma. Clinic staff take a blood draw, spin it so platelets gather, then place that liquid in the aching joint. Concentrated PRP contains more platelets.

For ongoing soreness, QC Kinetix has medical providers, the people who examine joints, available to discuss these shots and other knee or hip surgery alternatives.

Sources

1. A randomized trial in the New England Journal of Medicine compared physical therapy against intra-articular glucocorticoid injection for knee osteoarthritis and found physical therapy produced better WOMAC outcomes at one year. When a clinic offers an injection, the comparator that matters is not 'nothing' - it is a course of supervised exercise.

   Deyle GD, et al. — Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee.. The New England journal of medicine, 2020. DOI: 10.1056/NEJMoa1905877.

2. A systematic review of the discordance between clinical and radiographic knee osteoarthritis: many people with severe-looking x-rays have little pain, and many with disabling pain have modest radiographic change. This is the reason a post-treatment scan is a poor proxy for how someone feels, in either direction.

   Bedson J, et al. — The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature.. BMC musculoskeletal disorders, 2008. DOI: 10.1186/1471-2474-9-116.

3. The AAOS clinical practice guideline summary on SURGICAL management of knee osteoarthritis - the other end of the ladder, and the honest comparator for anyone told a biologic injection will let them avoid an operation.

   Srivastava AK, et al. — American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary of Surgical Management of Osteoarthritis of the Knee.. The Journal of the American Academy of Orthopaedic Surgeons, 2023. DOI: 10.5435/JAAOS-D-23-00338.

4. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446), and centres claimed a mean clinical efficacy of 82% (SD 9.6%) - a figure with no support in the published evidence. The gap between the quoted number and the trial data is the single most useful thing a patient can be told before a consultation.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. The journal of knee surgery, 2018. DOI: 10.1055/s-0037-1604443.

5. Medicare's National Coverage Determination covers autologous platelet-rich plasma ONLY for chronic non-healing diabetic, pressure or venous WOUNDS, and only under Coverage with Evidence Development inside an approved clinical research study. There is no Medicare coverage pathway for PRP as a treatment for osteoarthritis or any other joint indication, which is why these injections are quoted as cash prices.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2012.

6. Semi-structured interviews with 25 academic specialists - cardiology, ophthalmology, ORTHOPEDICS, pulmonology and neurology - on how they counsel patients asking about experimental stem cell and regenerative interventions. Orthopedists relied most heavily on informational approaches: explaining the science, sharing risks, providing principles. Reported challenges included wanting to support a patient's decision while worrying about harms, and addressing stem cell hype and unrealistic expectations.

   Smith C, et al. — Academic Physician Specialists' Approaches to Counseling Patients Interested in Unproven Stem Cell and Regenerative Therapies-A Qualitative Analysis.. Mayo Clinic proceedings, 2021. DOI: 10.1016/j.mayocp.2021.06.026.

7. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.

   Eckstein F, et al. — Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.. Annals of the rheumatic diseases, 2021. DOI: 10.1136/annrheumdis-2020-219181.

8. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.